Product image of Linezolid Kabi (Linezolid) supplied by GNH India

Linezolid Kabi

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Kabi (Linezolid)

Linezolid, the active ingredient in Linezolid Kabi, is an oxazolidinone presented as an injectable solution for intravenous use. It treats serious Gram‑positive bacterial infections such as MRSA, VRE, and various forms of pneumonia in adult patients.

GNH India supplies Linezolid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Fresenius Kabi S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Linezolid is an oxazolidinone antibiotic used to treat infections caused by resistant Gram‑positive bacteria.
  • Complicated skin and soft tissue infections: provides bacterial eradication and clinical cure in patients with MRSA‑related cellulitis.
  • Community‑acquired bacterial pneumonia: improves outcomes by targeting Streptococcus pneumoniae and atypical pathogens.
  • Nosocomial pneumonia: effective against hospital‑acquired Gram‑positive organisms, including multidrug‑resistant strains.
  • Methicillin‑resistant Staphylococcus aureus (MRSA) infections: achieves rapid bacterial clearance in bloodstream and deep‑tissue infections.
  • Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative mechanism of action for resistant enterococcal disease.

How It Works

  • Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex. This blockade halts translation of essential proteins, leading to bacteriostatic activity against susceptible Gram‑positive organisms, including strains resistant to other antibiotic classes.

Side Effects

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea: transient gastrointestinal upset occurring in many patients.
  • Diarrhea: loose stools that usually resolve after therapy completion.
  • Headache: mild to moderate cranial discomfort during treatment.
  • Rash: skin erythema or pruritus without systemic involvement.

Serious or Rare Side Effects

  • Thrombocytopenia: significant drop in platelet count requiring monitoring.
  • Peripheral neuropathy: sensory disturbances that may become irreversible.
  • Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperreflexia, and hyperthermia.

Precautions & Warnings

  • Before initiating Linezolid therapy, clinicians should consider several safety measures.
  • Monitor blood counts: regular CBCs to detect thrombocytopenia or anemia.
  • Assess renal function: dose adjustment may be needed in severe impairment.
  • Avoid serotonergic drugs: co‑administration can precipitate serotonin syndrome.
  • Use with caution in hepatic impairment: liver disease may affect drug clearance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
  • Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants): potential serotonin syndrome.
  • Sympathomimetic agents (pseudoephedrine, phenylephrine): may cause severe hypertension.

Moderate Interactions (Monitor Closely)

  • Warfarin: enhanced anticoagulant effect, monitor INR.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased bleeding risk.
  • Rifampin: induces metabolism, reducing linezolid plasma concentrations.

Frequently Asked Questions

Linezolid Kabi is indicated for serious Gram‑positive bacterial infections, including complicated skin and soft‑tissue infections, community‑acquired and nosocomial pneumonia, as well as infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE).

Linezolid binds to the 50S subunit of bacterial ribosomes, blocking the formation of the initiation complex needed for protein synthesis. This inhibition stops bacterial growth, providing a bacteriostatic effect against susceptible Gram‑positive organisms.

The dosing regimen for Linezolid Kabi is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the specific prescription provided.

The safety of Linezolid Kabi in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Linezolid Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Linezolid and vancomycin both target Gram‑positive bacteria, but linezolid is an oral and IV oxazolidinone with activity against some vancomycin‑resistant strains, while vancomycin is a glycopeptide primarily given IV. Linezolid offers a different mechanism of action and may be preferred for certain resistant infections or when renal toxicity is a concern.

Linezolid Kabi should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Maintaining the cold‑chain ensures product stability and potency.

Linezolid Kabi is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional under aseptic conditions, typically over a period of 30‑60 minutes, according to the prescribing information.

Serious risks include thrombocytopenia, peripheral neuropathy, serotonin syndrome when combined with serotonergic drugs, and rare cases of lactic acidosis or optic neuritis. Patients should be monitored regularly for hematologic changes and neurological symptoms.

Linezolid Kabi is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals taking MAO inhibitors, serotonergic agents, or those with uncontrolled hypertension due to potential drug interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linezolid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT